Breast cancer is a major health problem affecting millions of patients worldwide, and results in over 500,000 deaths annually. Previous studies have led to the classification of breast tumors into several molecular subtypes, with HER2-positive (HER2+) tumors representing ~25–30% of early-stage breast cancer patients’diagnoses [1–3]. HER2+ tumors are characterized at the molecular level by an amplification of a genomic region Breast cancer is a major health problem affecting millions of patients worldwide, and results in over 500,000 deaths annually. Previous studies have led to the classification of breast tumors into several molecular subtypes, with HER2-positive (HER2+) tumors representing ~25–30% of early-stage breast cancer patients’
diagnoses [1–3]. HER2+ tumors are characterized at the molecular level by an amplification of a genomic region specific mRNAs and long intergenic non-coding RNAs (lincRNAs) [5].